- Amended Report of Foreign Issuer (6-K/A)
February 10 2010 - 6:19AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For the
month of February, 2010
Commission
File Number
________________
Novogen
Limited
(Translation
of registrant’s name into English)
140 Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
o
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
o
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes
o
No
x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf
by the undersigned, thereunto duly
authorized.
Novogen
Limited
(Registrant)
/s/ Ron
Erratt
Ronald
Lea Erratt
Company
Secretary
Date
10 February, 2010
ASX
& MEDIA RELEASE
10
FEBRUARY, 2010
MARSHALL
EDWARDS, INC.’S ACTION INTENDED TO REGAIN COMPLIANCE WITH NASDAQ SHARE PRICE
RULE, BENEFIT SHAREHOLDERS
Novogen
Limited’s subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has just made the
following announcement.
NEW
CANAAN CT – February 9, 2010 – Marshall Edwards, Inc. (NASDAQ: MSHL), a
specialist oncology company focusing on the clinical development of novel
anti-cancer therapeutics, announced that its Board of Directors has approved a
reverse stock split of the company’s common stock. The Board’s
decision is intended to ensure that Marshall Edwards is in full compliance with
Nasdaq’s listing rules. The reverse stock split is subject to stockholder
approval.
As
previously announced, Marshall Edwards has until March 15, 2010, six months
after it was notified by Nasdaq that it was no longer in compliance with
Nasdaq’s share price listing standard, to regain compliance with such
standard. Per Nasdaq rules, Marshall Edwards will be in compliance
with the share price listing rule if at any time during the six month cure
period it has at least a $1.00 share price and has maintained at least a
$1.00 average closing share price over 10 consecutive trading
days. Prior to that that time, Marshall Edwards’ common stock
continues to be listed on Nasdaq and trades as usual. Marshall
Edwards is in compliance with all other Nasdaq listing rules.
Marshall
Edwards said it believes a reverse stock split would also benefit stockholders
because a higher price will make Marshall Edwards common stock more attractive
to a broader range of institutional and other investors.
Once
stockholders approve the split, Marshall Edwards’ Board intends to complete the
reverse stock split ratio of 1-for-10 so that 10 shares of issued and
outstanding common stock will convert into one share of common stock. The
price of each common share would increase by the same ratio so that a
stockholder would have fewer but higher priced shares, keeping the total
investment the same when the market opens on the date a split becomes
effective. A reverse stock split would not have any impact on the
voting and other rights of stockholders. Marshall Edwards said a reverse
stock split will have no impact on its business operations.
Marshall
Edwards plans to hold a special meeting of stockholders and complete the reverse
stock split in March, 2010. The time, date, location and other
details regarding the special meeting will be communicated to stockholders
at a later date via proxy material which will be filed with, and subject to the
review by the Securities and Exchange Commission (SEC). Marshall
Edwards’ Board has preliminarily set February 24, 2010 as the record date for
stockholders entitled to receive a proxy statement and vote at the special
meeting.
Marshall
Edwards encourages stockholders to read the proxy statement relating to the
special meeting when it becomes available because it will contain important
information. Stockholders may obtain a free copy of the proxy
statement and other documents (when available) that Marshall Edwards files with
the SEC at the SEC’s website at _www.sec.gov. When filed, the proxy
statement and these other documents may also be obtained for free from Marshall
Edwards by directing a request to Marshall Edwards, Inc., 140 Wicks Road, North
Ryde, New South Wales 2113, Australia, Attention: Company
Secretary.
About
Marshall Edwards, Inc.
Marshall
Edwards, Inc. is a specialist oncology company focused on the clinical
development of novel anti-cancer therapeutics. These derive from a
flavonoid technology platform, which has generated a number of novel compounds
characterised by broad ranging activity against a range of cancer cell types
with few side effects. The combination of anti-tumour cell activity
and low toxicity is believed to be a result of the ability of these compounds to
target an enzyme present in the cell membrane of cancer cells, thereby
inhibiting the production of pro-survival proteins within the
cell. Marshall Edwards has licensed rights from Novogen Limited (ASX:
NRT NASDAQ: NVGN) to bring four oncology drugs - phenoxodiol, triphendiol,
NV-143 and NV-128 - to market globally.
Marshall
Edwards is majority owned by Novogen Limited, an Australian biotechnology
company that is specialising in the development of therapeutics based on a
flavonoid technology platform. Novogen is developing a range of
therapeutics across the fields of oncology, cardiovascular disease and
inflammatory diseases. More information on phenoxodiol and on the
Novogen group of companies can be found at
www.marshalledwardsinc.com
and
www.novogen.com
.
Under
U.S. law, a new drug cannot be marketed until it has been investigated in
clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not historical
in nature are "forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995. You
should be aware that our actual results could differ materially from those
contained in the forward-looking statements, which are based on management's
current expectations and are subject to a number of risks and uncertainties,
including, but not limited to, our failure to successfully commercialize our
product candidates; costs and delays in the development and/or FDA approval, or
the failure to obtain such approval, of our product candidates; uncertainties in
clinical trial results; our inability to maintain or enter into, and the risks
resulting from our dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization, marketing, sales
and distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice; and
one-time events. We do not intend to update any of these factors or to publicly
announce the results of any revisions to these forward-looking
statements.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024